Is There Any Advantage of Treating Partners in Helicobacter pylori Eradication?

Abstract EN

Aim.

We designed this trial to find answers to the following questions.

(1) Does the success rate decrease in a country where HP prevalence is high? (2) Can we provide benefit by simultaneously treating the partners of infected patients? Materials and Methods.

The first group consisted of 102 HP-positive patients, and both the patients and their HP-positive partners were treated.

The second group consisted of 104 HP-positive patients whose partners were HP-positive but only the patients were treated.

The participants in both groups were treated with levofloxacin 500 mg daily, amoxicillin 1 g b.i.d, and lansoprazole 30 mg b.i.d (LAL) for ten days.

Results.

In the per-protocol analysis, the eradication success rate was found to be 92.2% (94/8) in the first group and 90.4% (94/10) in the second group.

No statistically significant difference was found between the two groups (P>0.05).

Conclusions.

With regard to the HP eradication rate, no difference was found between treating the HP-positive partners of HP-positive patients simultaneously and not treating them simultaneously.

According to these results, we can say that reinfections between partners do not significantly contribute to the failure of eradication.